Work

The IRX-2 regimen combined with nivolumab in recurrent/metastatic solid tumors: A phase 1b study to evaluate the safety, determine recommended phase 2 dose (RP2D), and investigate the biologic and clinical activity.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.tps2662

Authors: Rohit K. Jain, Jingsong Zhang, Zeynep Eroglu, Ben C. Creelan, Andrew Scott Brohl, Michael Rahman Shafique, Jhanelle Elaine Gray, Jameel Muzaffar, Julia Ida, Mensura Lacevic, Youngchul Kim, Christine H. Chung, Solmaz Sahebjam

Institutions: Moffitt Cancer Center, University of South Florida

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2946910221

Cites:

Cited by: 1

Related to: 10